Idorsia
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.
Launch date
Employees
Market cap
AUD420m
Enterprise valuation
AUD1.9b (Public information from Sep 2024)
Share price
CHF1.525 IDIA.SW
Company register number CH-280.3.020.963-7
Allschwil Canton of Basel-Landschaft (HQ)
Financials
Estimates*
| CHF | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 71.8m | 35.3m | 97.1m | 152m | 115m | 204m | 365m |
| % growth | 201 % | (51 %) | 175 % | 57 % | (24 %) | 77 % | 79 % |
| EBITDA | (421m) | (589m) | (783m) | (542m) | (230m) | (288m) | (71.0m) |
| % EBITDA margin | (586 %) | (1666 %) | (806 %) | (356 %) | (199 %) | (141 %) | (19 %) |
| Profit | (445m) | (635m) | (828m) | (298m) | (287m) | (335m) | (93.3m) |
| % profit margin | (620 %) | (1795 %) | (853 %) | (196 %) | (249 %) | (164 %) | (26 %) |
| EV / revenue | 53.4x | 121.4x | 34.7x | 8.9x | 10.1x | 6.7x | 2.9x |
| EV / EBITDA | -9.1x | -7.3x | -4.3x | -2.5x | -5.1x | -4.8x | -15.0x |
| R&D budget | 381m | 414m | 383m | 294m | - | - | - |
| R&D % of revenue | 531 % | 1172 % | 395 % | 193 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | Corporate spinout | |
| N/A | N/A | IPO | |
* | $1.4m | Grant | |
* | N/A | CHF330m | Post IPO Equity |
| N/A | $632m | Post IPO Equity | |
* | N/A | CHF75.0m | Post IPO Debt |
| Total Funding | AUD2.2m | ||
